Bayer and Ardea in Cancer Drug Deal

By Taskin Ahmed

Pharma Deals Review: Vol 2009 Issue 4 (Table of Contents)

Published: 29 Apr-2009

DOI: 10.3833/pdr.v2009.i4.1101     ISSN: 1756-7874

Section: Licensing



Bayer has entered into a global agreement with San Francisco-based Ardea Biosciences focused on the development of mitogen-activated ERK kinase inhibitors for the treatment of solid tumours...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details